National Distributor to Sell Cold Sore Prevention Device Through National Ecommerce Sales Through Direct to Consumer Marketing Efforts Toronto, Ontario--(Newsfile Corp. - March 13, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that the Company has... Read More

Announces Shares for Debt Settlements Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the addition of Steve Raysely to its Advisory Board. With deep experience in healthcare and technology sales, marketing and operations, Mr.... Read More

National Distributor Eager To Begin Sales & Marketing Of Vascular Compression Therapy Solutions Toronto, Ontario--(Newsfile Corp. - January 21, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that it has secured a purchase order for 1,750 Venowave VW5... Read More

National Distributor And Its Network Receive Upwards Of 100 Doctor Referrals Per Day For Vascular Compression Therapy Solutions Toronto, Ontario--(Newsfile Corp. - January 13, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that the Company has secured... Read More

Toronto, Ontario--(Newsfile Corp. - January 3, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that the Company has negotiated a debt settlement with arm's length creditor. Pursuant to the debt settlement it has arranged, and subject to acceptance by... Read More

Initiative Includes Milestone-Based Inventory Purchase Commitments During Q1 and Q2, 2025 Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce the Company has signed a letter of intent (LOI) for a Venowave... Read More

Inretio presents initial clinical trial results at prestigious BRAIN Conference 2024 in London. Toronto, Ontario--(Newsfile Corp. - December 11, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, congratulates its investment partner Inretio on the success of the first phase of... Read More

Distributors' medical partner networks impressed with Venowave device, speed of Medicare/Medicaid processing and prepare roadmaps to drive sales Toronto, Ontario--(Newsfile Corp. - December 5, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce that its... Read More

Toronto, Ontario--(Newsfile Corp. - November 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment partner in advanced diagnostic and medical device technologies, has completed its announced strategic review, and has set the course to spin-off the Company's Consumer Product Portfolio into its own separate publicly traded company. This move is aimed at strengthening Therma Bright's... Read More

Toronto, Ontario--(Newsfile Corp. - November 11, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that the Company has negotiated debt settlements with arm's length creditors. Pursuant to the debt settlements it has arranged, and subject to acceptance... Read More

InStatin to secure exclusive worldwide licensing agreement of InVixa's inhaled statin solution to prevent and treat acute lung disease Toronto, Ontario--(Newsfile Corp. - October 28, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF), a leading developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce a significant development with its investment partners, InStatin... Read More

Toronto, Ontario--(Newsfile Corp. - October 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma Bright" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces further to its press release of September 18, 2024, it has now issued an aggregate of 5,056,250 common shares at a deemed price of $0.08 per... Read More

Quantify Medical Sees Initial Success with Venowave VW5 Sales and Medicare/Medicaid Reimbursement Test Therma Bright Closes First Tranche of Non-Brokered Concurrent Private Placement for CAD $174,900 Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary... Read More

LIFE Financing and Concurrent Private Placement to Include Common Shares Only and no Warrants Toronto, Ontario--(Newsfile Corp. - September 27, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (" Therma Bright " or the " Company "), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it will be conducting a non-brokered... Read More

Clinical research will offer insight for specific targeting of active pharmaceutical ingredients (API) that will further support Phase 1 Human Trials. Toronto, Ontario--(Newsfile Corp. - September 23, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in cutting-edge diagnostic and medical device technologies, extends its congratulations to strategic... Read More

Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that AI4LYF has agreed to participate in a shares for debt transaction which progresses the Company's contractual obligation to AI4LYF while preserving... Read More

New Advisory Board Member will focus on Venowave sales and business development efforts Toronto, Ontario--(Newsfile Corp. - September 12, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the addition of Douglas S. Sommerville to its Advisory Board. With 30 years of experience in... Read More

Chairman of Therma Bright's Strategic Investment Partner Recognized for Outstanding Research and Discovery in Respiratory Drug Delivery Toronto, Ontario--(Newsfile Corp. - September 4, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in cutting-edge diagnostic and medical device technologies, extends its congratulations to strategic investment partner... Read More

Game-Changing Innovation Poised to Transform Stroke and Blood Clot Treatment Therma Bright's Strategic Investment Helps Medical Device Company Demonstrate Efficacy and Safety in Transforming Ischemic Stroke Care Toronto, Ontario--(Newsfile Corp. - August 27, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge,... Read More

Nationwide partner launches initial Venowave sales program to gauge Medicare/Medicaid reimbursement timelines and billing procedures Post initial program success, distributor commits to acquire remaining inventory that totals up to USD $2.38M in reimbursement value Toronto, Ontario--(Newsfile Corp. - August 23, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and... Read More

Nationwide partner launches initial Venowave sales program to gauge Medicare/Medicaid reimbursement timelines and billing procedures Post initial program success, distributor commits to acquire remaining inventory that totals up to USD $2.38M in reimbursement value Toronto, Ontario--(Newsfile Corp. - August 22, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and... Read More

The device becomes the first-of-its-kind Durable Medical Equipment to receive a new HCPCS Level II designation Company looks to provide a U.S. sales update in the coming week Toronto, Ontario--(Newsfile Corp. - August 19, 2024) - Therma Bright Inc . (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device... Read More

Toronto, Ontario--(Newsfile Corp. - August 16, 2024) - Therma Bright Inc . (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it's AI-powered Digital Cough Technology (DCT), with development partner AI4LYF, is currently being considered as a partner technology for a new... Read More

New Advisory Board Member Will Initially Focus On Venowave Sales & Business Development Toronto, Ontario--(Newsfile Corp. - August 13, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce the Company has added Michael Raimondo, a 30-year veteran in... Read More

Toronto, Ontario--(Newsfile Corp. - August 6, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its InStatin investment. With the recent capital raise, the Company has advanced funds to expand its investment in InStatin, as part of... Read More

Company anticipates CMS permanent CPT(R) and HCPCS codes in the coming days Toronto, Ontario--(Newsfile Corp. - August 1, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide a quick update from a recent notification from US Department of Health and... Read More

Toronto, Ontario--(Newsfile Corp. - July 29, 2024) - Therma Bright Inc . (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company has received the U.S. Food and Drug Administration's (FDA) approval on its 510K application request to correct the Venowave VW5... Read More

Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that, subject to regulatory approval, it has engaged the services of Independent Trading Group ("ITG") to provide market-making services in accordance... Read More

Medical Device Developer & Investor Taps 4 Markets With Growth Projections of USD $39.1B by 2030 Toronto, Ontario--(Newsfile Corp. - July 3, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to provide a market update on the state of the business, including:... Read More

Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it has completed the second and final tranche ("Final Tranche") of its previously announced $1,000,0000 non-brokered private placement (the... Read More

Toronto, Ontario--(Newsfile Corp. - June 19, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, announces that further to its press release of May 22, 2024, it has now issued an aggregate of 19,250,000 common shares at a deemed price of $0.01 per share to settle... Read More

Toronto, Ontario--(Newsfile Corp. - June 10, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that it has completed the first tranche ("First Tranche") of its previously announced non-brokered private placement (the "Offering"). Under the First... Read More

Toronto, Ontario--(Newsfile Corp. - May 22, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that it proposes to undertake a non-brokered private placement of up to 100,000,000 units priced at $0.01 per unit for total proceeds of $1,000,000 (the "Offering"). Each unit... Read More

Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced that its Board of Directors ("the Board") has initiated a review process to review, evaluate and explore a broad range of strategic initiatives and alternatives with the intent... Read More

Company To Resume Trading on Toronto Stock Exchange Venture (TSXV) on February 7, 2024 Toronto, Ontario--(Newsfile Corp. - February 6, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, has received a letter from the Center of Medicare and Medicaid. The letter confirms that CMS is... Read More

Toronto, Ontario--(Newsfile Corp. - December 5, 2023) - Therma Bright Inc. ( TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that a cease trade order has been issued by the Ontario Securities Commission for not filing the following documents by the periodic disclosure deadline: annual financial... Read More

Company's DCA Solution Offers Robust Set of User and Medical Practitioner Features via an Android & iOS Mobile App and a Clinician Dashboard For Monitoring Patient's Cough Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies,... Read More

Toronto, Ontario--(Newsfile Corp. - November 2, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company has opened its existing and new distribution channels for its Venowave device. Each channel partner has expressed an interest in the Venowave... Read More

NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ: THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company’s Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice... Read More

Toronto, Ontario--(Newsfile Corp. - September 29, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that Mr. Eric Myung, CPA, CA, has taken on the role of CFO. Mr. Myung will assume his CFO role effective immediately. Mr. Myung is a senior financial analyst at... Read More

Toronto, Ontario--(Newsfile Corp. - September 29, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that it has changed its auditors from HS & Partners LLP (" Former Auditor ") to Zeifmans LLP (" Successor Auditor "). At the request of the Company, the Former Auditor was... Read More

InStatin & InVixa Are Developing Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD) Toronto, Ontario--(Newsfile Corp. - September 27, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announces that it has entered... Read More

Toronto, Ontario--(Newsfile Corp. - September 13, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company has signed Hero LifeCare ( herolifecare.com ) to be a U.S. distribution partner for marketing and selling the Venowave device. Hero LifeCare ("Hero"), a... Read More

Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company has submitted an updated U.S. Food and Drug Administration (FDA) 510K application to correct the Venowave device's intended use, labeling and product... Read More

Toronto, Ontario--(Newsfile Corp. - August 22, 2023) - Therma Bright Inc . (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today that the Company has heard back from the Centers for Medicare and Medicaid Services (CMS) on its application for the nine (9) unique permanent Current Procedural... Read More

Toronto, Ontario--(Newsfile Corp. - August 4, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today that it expects a final decision regarding the issuance of the unique permanent Current Procedural Terminology (CPT®) / Healthcare Common Procedure Coding System (HCPCS)... Read More

Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced that on May 31, 2023, representatives from Therma Bright Inc and the U.S. Department of Health and Human Services (DHHS) engaged in productive discussions regarding the... Read More

Company Sees Benefits For Healthcare Practitioners, Businesses and Governments To Better Collect, Capture And Analyze Critical Respiratory Data Toronto, Ontario--(Newsfile Corp. - June 22, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today it has begun investigating... Read More

Both Companies Anticipates Approval to Launch of Human Clinical Trials Tel Aviv, Israel and Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, and its investment Inretio Inc., an innovative Israeli medical device company , has announced the... Read More

Toronto, Ontario--(Newsfile Corp. - May 25, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company is working with its U.S distributor network on expanding sales of Venowave under the nine (9) temporary Current Procedural Terminology (CPT®) and... Read More

Toronto, Ontario--(Newsfile Corp. - May 10, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company has established collaborations with several Tuberculosis (TB) medical care facilities to initiate the data collection and screening of active... Read More

Toronto, Ontario--(Newsfile Corp. - April 21, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer and investor in a range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that further to its news releases of January 19 and March 6, 2023, relating to its acquisition of up to 25% of Inretio Inc., it has now paid the portion of the... Read More

Toronto, Ontario--(Newsfile Corp. - April 14, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company has successfully secured U.S. Medicare and Medicaid reimbursement through various payers. The reimbursement per pair of Venowave devices, under these... Read More

Toronto, Ontario--(Newsfile Corp. - March 23, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company and AI4LYF are preparing to launch DCT, its digital cough data collection and screening smartphone application. On February 16, 2023, Therma Bright... Read More

New Space Offers Advanced Development Capabilities for the PREVA (TM) Clot Removal Device for Ischemic Stroke Treatment Toronto, Ontario--(Newsfile Corp. - March 8, 2023) - Investor partner Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its partnership with... Read More

Dr. John Patton is recognized as a Leader in the Inhaled Formulation Solutions To Bring Industry Expertise To Innovative, Research-Based Pharmaceutical Firm Toronto, Ontario--(Newsfile Corp. - March 1, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and investor in a range of leading-edge and proprietary diagnostic and medical technologies, is pleased to announce that Dr. John... Read More

Toronto, Ontario--(Newsfile Corp. - February 23, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a range of leading edge, proprietary diagnostic and medical device technologies, is pleased to provide an update on its partnership with Inretio Inc. ("Inretio"), a leading Israeli medical device startup developing a novel clot removal device for use in treating... Read More

Toronto, Ontario--(Newsfile Corp. - February 16, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has finalized and signed the exclusive worldwide licensing rights to market and sell AI4LYF's Digital Cough... Read More

Toronto, Ontario--(Newsfile Corp. - January 19, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has signed a SPA (Share Purchase Agreement) with Inretio Ltd. ("Inretio") for its innovative protective blood clot... Read More

Toronto, Ontario--(Newsfile Corp. - December 21, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide a summary of activities and accomplishments achieved during 2022 as outlined below. AcuVid™ Health Canada continues to provide... Read More

Toronto, Ontario--(Newsfile Corp. - December 1, 2022) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into an agreement to acquire an interest in a novel technology that utilizes inhaled statins for the treatment of... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has entered into a letter of intent ("LOI") with AI4LYF LLC ("AI4LYF") for the exclusive licensing rights for a digital cough-based diagnosis screening technology. Digital... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has received new temporary PDAC (Pricing, Data Analysis and Coding) billing codes for its Venowave product giving Therma Bright immediate access to reimbursement through Medicare... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that the initial order of its updated Venowave product has been sold to customers in the US by our exclusive distributor, DME Authority. Therma Bright is pleased to announce it has received... Read More

Therma Bright Inc . (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, provides an update on it AcuVid™ COVID-19 Rapid Antigen Saliva Test's Emergency Use Authorization application with the U.S. Food and Drug Administration. The Company has received communication from the FDA which states they... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide the following update for Its AcuVid™ COVID-19 Rapid Antigen Saliva Test. Therma continues to communicate with the FDA regarding its EUA application for its AcuVid™ COVID-19 Rapid Antigen... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the submission of its Health Canada application for the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point-of-Care Use (PoC). The HC application includes all the updated... Read More

Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive medical device technologies, is pleased to provide an update for the Company's AcuVid™ COVID-19 Rapid Antigen Saliva Test and its U.S. Food and Drug Administration's Emergency Use Authorization application process. The Company's Executive and Product Development teams... Read More

Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it will submit an application to Health Canada for review of the Company's AcuVid™ COVID-19 Rapid Antigen Saliva Test for detecting SARS CoV-2 virus in saliva. The application to Health Canada follows an application under the Emergency Use Authorization (EUA) guidelines to the U.S. Food &... Read More

Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company and developer of the AcuVid™ Covid-19 Rapid Antigen Saliva Test, is pleased to announce that the initial order of its updated Venowave product has been shipped to its US distributor, DME Authority, LLC, from Therma's Chinese contract manufacturer. As previously announced on December 16, 2021 the initial order consists... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the submission of its U.S. Food & Drug Administration's (FDA) Emergency Use Authorization (EUA) application for its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point of... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the Company has been recognized in the 2022 TSX Venture 50 for top performing stocks, and ranked in the top three (3) for the Life Sciences sector. The 2022 TSX Venture 50 winners were... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that on February 4, 2022 the U.S. Patent and Trademark Office allowed a U.S. patent application (US 15/787,599) which covers a device that can apply heat and antimicrobial treatment through... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce its AcuVid™ COVID-19 Rapid Antigen Saliva Test for Point of Care (PoC) has successfully exceeded U.S. Food & Drug Administration's (FDA) Emergency Use Authorization (EUA) requirements for... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announced today that its U.S. Clinical Performance Study is still underway. Once the clinical data has been completed and tabulated, the final results will be reported to the marketplace and the U.S. Food & Drug... Read More

Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to confirm that antibodies incorporated in its AcuVid™ COVID-19 Rapid Antigen Saliva Test have been tested and can successfully detect the new, highly transmissible COVID-19 Omicron B.1.1.529 variant. Ever since the... Read More

Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company") , developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce it has signed an agreement with a contract manufacturer to produce a weekly minimum of 500,000 AcuVid™ COVID-19 Rapid Antigen Saliva Tests in order to meet the new U.S. Food and Drug Administration's... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the launch of its eCommerce site - https://www.benepod.com just in time for the 2021... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it will begin its U.S. clinical performance study with the receipt of Institutional Review Board's (IRB) conditional approval late yesterday, Thursday, November 11, 2021. The clinical... Read More

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, announces that Therma has been in communication with the FDA over the intervening period since the initial submission of its AcuVid™ COVID-19 Rapid Antigen Saliva Test. Therma has responded to the FDA questions... Read More